Elbasvir

from Wikipedia, the free encyclopedia
Structural formula
Structure of Elbasvir
General
Surname Elbasvir
other names
  • MK-8742
  • N - [(2 S ) -1 - [(2 S ) -2- [5 - [(6 S ) -3- [2 - [(2 S ) -1 - [(2 S ) -2- (methoxycarbonylamino ) -3-methylbutanoyl] pyrrolidin-2-yl] -1 H -imidazol-5-yl] -6-phenyl-6 H -indolo [1,2- c ] [1,3] benzoxazin-10-yl] - 1 H -imidazol-2-yl] pyrrolidin-1-yl] -3-methyl-1-oxobutan-2-yl] carbamic acid methyl ester ( IUPAC )
Molecular formula C 49 H 55 N 9 O 7
External identifiers / databases
CAS number 1370468-36-2
EC number 806-907-5
ECHA InfoCard 100.234.242
PubChem 71661251
ChemSpider 30843797
DrugBank DB11574
Wikidata Q19904043
properties
Molar mass 882.015 g mol −1
safety instructions
GHS labeling of hazardous substances
no GHS pictograms
H and P phrases H: no H-phrases
P: no P-phrases
As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions .

Elbasvir is a medicinal and antiviral drug used to treat infections with the hepatitis C virus .

properties

Elbasvir belongs to a group of NS5A inhibitors . It binds to the non-structural protein 5A of the hepatitis C virus of genotypes 1 and 4, as well as daclatasvir , samatasvir , ledipasvir , MK-8408 , odalasvir , ombitasvir , ravidasvir and velpatasvir . Elbasvir is administered orally at 50 mg as a combination preparation with the NS3 / 4A inhibitor grazoprevir at 100 mg. The drug approval of the combination preparation for the genotypes HCV1 and HCV4 took place in 2016 in the USA. This was followed by approvals for Canada, Switzerland and the European Union (July 22, 2016).

Trade names

Individual evidence

  1. ↑ a b Sigma-Aldrich / Advanced ChemBlocks: Elbasvir - ADV947321183 , accessed on October 13, 2017
  2. ↑ M. El Kassas, T. Elbaz, Y. Abd El Latif, G. Esmat: Elbasvir and grazoprevir for chronic hepatitis C genotypes 1 and 4. In: Expert review of clinical pharmacology. Volume 9, Number 11, November 2016, pp. 1413-1421, doi: 10.1080 / 17512433.2016.1233813 , PMID 27603877 .
  3. ↑ FDA approves Zepatier for treatment of chronic hepatitis C genotypes 1 and 4 . January 28, 2016.
  4. ↑ European Medicines Agency - Find medicine - Zepatier. Retrieved December 16, 2017 .